The healthcare community is closely watching the novel dual-action agent, a dual-action agonist targeting both glucose metabolism and GIP. Preliminary studies suggest it could offer meaningful gains in obesity management compared to existing synedica retatrutide treatments, perhaps representing a major step forward in the tackling of a challenging